Inhaled EXO-CD24 kept 85% of patients with ARDS free of respiratory failure at day 7 vs 33.3% with placebo in a 90-patient phase 2b trial.
|Articles|December 1, 2014
- BioPharm International-12-01-2014
- Volume 27
- Issue 12
Purification Resin Increases Efficiency
Tosoh Bioscience’s CaPure-HA hydroxyapatite chromatography resin is designed for the purification of monoclonal antibodies, polyclonal antibodies, and antibody fragments, and the separation of antibody isoforms and isozymes.
Advertisement
Tosoh Bioscience’s CaPure-HA hydroxyapatite chromatography resin is designed for the purification of monoclonal antibodies, polyclonal antibodies, and antibody fragments, and the separation of antibody isoforms and isozymes. The resin has a pressure rating of 10 MPa, a mean particle size of 39 μm, a pH stability of 6.5-14, and alkaline stablility in 0.5 mol/L NaOH for greater than 50 CIP cycles.
The dynamic binding capacity, at 10% breakthrough, is greater than 20 g/L for lysozyme at residence times as low as one minute, greater than 30 g/L for human lgGs at residence times as low as two minutes, and greater than 50 g/L for human lgGs at residence times of five minutes.
Tosoh Bioscience
Articles in this issue
almost 12 years ago
The Biopharma Working Lifealmost 12 years ago
FDA Realigns Drug Inspection and Manufacturing Oversightalmost 12 years ago
Year in Review: Key Outsourcing Trendsalmost 12 years ago
Improving PAT for Biologicsalmost 12 years ago
Job Security and Salaries Trend Upwardalmost 12 years ago
A Next Generation of Quality Managementalmost 12 years ago
BioPharm International, December 2014 Issue (PDF)Advertisement
Related to this article
Nuravax will test AV-1959R in a 160-adult phase 2 trial to see whether the amyloid vaccine can prevent Alzheimer disease before symptoms begin.
In the phase 3 SHINE-2 trial, half of pediatric patients who responded to mirikizumab induction were in clinical remission at week 52. Lilly plans to file for a pediatric UC label expansion.
Guselkumab (Tremfya) sustained perianal fistula healing through 1 year in Crohn disease, with remission climbing to 35% in one FUZION dosing arm.
Interim phase 1/2 data presented at Retina in Rio 2026 showed sustained visual improvements with Opus Genetics’ AAV8 gene therapy OPGx-LCA5 and improved retinal sensitivity with OPGx-BEST1 in inherited retinal diseases.
Nathan Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Mirikizumab (Omvoh) achieved comprehensive disease control in 27.7% of UC patients and deep remission in 20.4% with Crohn disease at 1 year.
As ArsenalBio, TScan, Bristol Myers Squibb, and others abandon ex vivo programs for in vivo engineering, early clinical data and platform differences point to both the promise and the unresolved safety, manufacturing, and regulatory questions of generating CAR-T cells inside the body.
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
4
Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation
5